Developer docs
API playgroundTry for free, no card

Search company profiles

CellMax Life

Full company profile

uuid0002ilj

Namestring
CellMax Life
Legal namestring
CellMax, Inc.
Websiteurl
cellmaxlife.com
Company typeenum
Private
Founded yearint
2012
Descriptiontext

CellMax Life is a private molecular diagnostics company founded in 2012 by Atul Sharan and headquartered in Sunnyvale, California, with a secondary office in New Taipei City, Taiwan. The company has developed a proprietary liquid biopsy platform called CMx (Circulating Epithelial Cell Bio-Mimetic) that detects circulating epithelial cells (CECs) shed from precancerous and cancerous lesions into the bloodstream. Its lead commercial product, FirstSightCRC, is a non-invasive multimodal blood test combining CEC detection with somatic mutation and methylation analysis from cell-free tumor DNA. The test is processed in the company's CLIA-certified and CAP-accredited laboratory in Sunnyvale and reports a binary positive/negative result. Published clinical performance includes an AUC of 0.897 for adenoma detection and 0.958 for colorectal cancer detection, with 100% sensitivity (95% CI: 71.5%-100%) for CRC and 75.5% sensitivity (95% CI: 61.7%-86.2%) for advanced adenomas at 90% specificity in external validation.

The company targets average-risk adults aged 45 and older — a population of 125+ million Americans recommended for routine colorectal cancer screening under USPSTF, NCCN, and American Cancer Society guidelines — for whom colonoscopy compliance is below 40%. A secondary use case is post-polypectomy surveillance risk stratification. FirstSight is physician-ordered and not available direct-to-consumer; revenue is generated through laboratory diagnostic testing services on samples sent to the Sunnyvale lab. CellMax secured FDA Breakthrough Device Designation for FirstSight in August 2021 and entered a strategic development and commercialization partnership with Sebela Pharmaceuticals in March 2021 alongside its Series C financing.

The company is led by CEO and co-founder Atul Sharan, with CSO and VP of R&D Rui Mei (PhD, ex-Centrillion Biosciences), Chief Technology Advisor John Sninsky (PhD, former CSO of CareDx, 30+ years across Roche Molecular Systems, Celera, and Quest Diagnostics), and Sr. VP of Clinical Studies and Biostatistics Drew Watson (PhD, ex-Genomic Health where he led the pivotal Oncotype DX trial). The company operates with 51-100 employees, a global R&D team, and protects its core technology with 16 patents covering the microfluidic chip, colon-specific antibodies, and air-foam release mechanism.

Short descriptiontext

CellMax Life is a private molecular diagnostics company that has developed the FirstSightCRC blood test, a non-invasive multimodal liquid biopsy using its proprietary CMx circulating epithelial cell platform for early detection of colorectal cancer and pre-cancerous adenomas, serving average-risk adults aged 45 and over through physician-ordered testing.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSunnyvale, United States
HQ citystring
Sunnyvale
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
liquid biopsy diagnostics, colorectal cancer screening, circulating tumor cells, early cancer detection, molecular diagnostic tests
Industry5 codes
PRIMARYHLAAANAG
Liquid Biopsy & Minimal Residual Disease (MRD) Precision Testing
SECONDARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
SECONDARYHLAAAMAH
Liquid Biopsy Biomarkers (ctDNA/ctRNA/CTCs/exosomes)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAGAEAB
Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
NAICS code2 codes
  • Medical Laboratories621511
  • Medical and Diagnostic Laboratories62151
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Medical Laboratories8071
Product category
Cancer Diagnostics
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Laboratory Diagnostic Testing Services
TypeOne Time License
Description

CellMax Life generates revenue through providing CLIA-certified and CAP-accredited laboratory testing services for its FirstSight blood test. The test is performed on blood samples collected by healthcare providers and processed in their certified laboratory.

cellmaxlife.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1FirstSight
Description

FirstSight™ - the first blood test for colon cancer screening and prevention. A multimodal liquid biopsy test that detects circulating gastrointestinal epithelial cells (CECs) and genomic markers (mutations and methylation) in a single blood sample for early detection of colorectal cancer and precancerous adenomas.

cellmaxlife.com
Core offering1 text field

CellMax Life develops and commercializes non-invasive blood-based diagnostic tests for early cancer detection, with its flagship FirstSightCRC test screening for colorectal cancer and precancerous adenomas. The tests leverage a proprietary Circulating Epithelial Cell Bio-Mimetic (CMx) platform combining microfluidic cell capture with multimodal biomarker (mutation, methylation) analysis. Testing is performed in the company's CLIA-certified and CAP-accredited laboratory in Sunnyvale, California, with samples ordered through healthcare providers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Reduces mortality from colorectal cancer by 53% through adenoma detection and removal
+2 more records
Product overview1 text field

CellMax Life offers a portfolio of non-invasive blood tests for cancer screening and early detection, anchored by the FirstSightCRC blood test for colorectal cancer and pre-cancer detection. The company's proprietary CMx platform (Circulating Epithelial Cell Bio-Mimetic) forms the core technology foundation, utilizing a patented microfluidic chip with colon-specific antibodies and air-foam cell release mechanism. The test analyzes circulating gastrointestinal epithelial cells (CECs) along with mutation and methylation data through proprietary algorithms. The company also operates multi-biomarker platforms covering next generation sequencing (NGS), methylation, and protein expression. CellMax Life is headquartered in Sunnyvale, California with a CLIA certified and CAP accredited laboratory at this location.

Product and service2 records
1FirstSightCRC (FirstSight™)
CategoryCancer Diagnostics
Description

A non-invasive multimodal blood test for early detection of colorectal cancer and pre-cancerous adenomas (precancerous polyps). The test uses the proprietary CMx platform to detect circulating precancer and cancer cells shed into the blood during early cancer development, combining circulating gastrointestinal epithelial cell (CEC) detection with mutation and methylation analysis. Reports results as positive or negative.

2Multi-biomarker Platforms
CategoryCancer Diagnostics
Description

Comprehensive biomarker detection platforms covering precancer and cancer cell detection, next generation sequencing (NGS), methylation, and protein expression platforms for multi-marker cancer screening and detection.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-03-23
Description

Strategic development and commercialization partnership for FirstSight blood test for detection of colorectal cancer and pre-cancer. CellMax Life closed Series C financing to accelerate development and regulatory approvals of FirstSight in conjunction with this partnership.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Clinical-grade molecular diagnostics company offering cell-free DNA tests across oncology, women's health, and organ health. Comparable to CellMax in deploying proprietary cfDNA/cell-based assays from a CLIA-certified lab and selling into physician channels.

2GRAIL
TypeEmerging player
Description

Developer of the Galleri multi-cancer early detection blood test using methylation-based ctDNA analysis. Comparable to CellMax in targeting non-invasive blood-based cancer screening, though broader in indication scope (multi-cancer vs. CRC-focused).

TypeBroad incumbent
Description

Specialty diagnostics company focused on transplant and immune disorder monitoring, with prior CSO Dr. John Sninsky now advising CellMax. Comparable as a publicly traded specialty molecular diagnostics company operating CLIA-certified lab services and engaging in PMA-style clinical evidence generation.

TypeDirect peer
Description

Developer of Cologuard, the leading FDA-approved non-invasive stool-based colorectal cancer screening test, and Thrive Earlier Detection (acquired). Direct competitor to FirstSight in the non-invasive CRC screening category, with established Medicare coverage and broad physician adoption.

TypeBroad incumbent
Description

One of the largest clinical laboratory services companies in the U.S., offering a broad menu of diagnostic tests including oncology and genetics. Comparable to CellMax as a scaled reference lab operator with physician ordering workflows and payer relationships.

TypeDirect peer
Description

Developer of the Shield blood-based CRC screening test and a leading liquid biopsy oncology diagnostics franchise. Directly comparable to CellMax in blood-based CRC detection technology, target customer (prescribing physicians), and business model (lab-developed test services).

TypeEmerging player
Description

China- and U.S.-based cancer screening diagnostics company developing blood-based methylation assays for early cancer detection. Comparable to CellMax in pursuing non-invasive blood-based cancer screening, particularly relevant given CellMax's Taiwan R&D footprint.

TypeEmerging player
Description

Multiomics blood-based early cancer detection company with a lead colorectal cancer screening program (PREEMPT CRC). Comparable to CellMax in deploying proprietary blood-based biomarker assays for early cancer detection and competing for similar screening populations.

TypeEmerging player
Description

Early-detection company developing a blood-based methylated DNA platform for multi-cancer detection. Comparable to CellMax in deploying next-generation liquid biopsy technology for early cancer screening from a clinical-grade lab.

TypeBroad incumbent
Description

Now part of Exact Sciences, Genomic Health pioneered Oncotype DX and established clinical-grade genomic diagnostics with Medicare coverage. Relevant incumbent comparable to CellMax in operating CLIA-certified molecular diagnostic labs and pursuing reimbursement-driven commercial models.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

CellMax Life

Cancer Diagnosticscellmaxlife.com

CellMax Life is a private molecular diagnostics company that has developed the FirstSightCRC blood test, a non-invasive multimodal liquid biopsy using its proprietary CMx circulating epithelial cell platform for early detection of colorectal cancer and pre-cancerous adenomas, serving average-risk adults aged 45 and over through physician-ordered testing.

What CellMax Life does

CellMax Life is a private molecular diagnostics company founded in 2012 by Atul Sharan and headquartered in Sunnyvale, California, with a secondary office in New Taipei City, Taiwan. The company has developed a proprietary liquid biopsy platform called CMx (Circulating Epithelial Cell Bio-Mimetic) that detects circulating epithelial cells (CECs) shed from precancerous and cancerous lesions into the bloodstream. Its lead commercial product, FirstSightCRC, is a non-invasive multimodal blood test combining CEC detection with somatic mutation and methylation analysis from cell-free tumor DNA. The test is processed in the company's CLIA-certified and CAP-accredited laboratory in Sunnyvale and reports a binary positive/negative result. Published clinical performance includes an AUC of 0.897 for adenoma detection and 0.958 for colorectal cancer detection, with 100% sensitivity (95% CI: 71.5%-100%) for CRC and 75.5% sensitivity (95% CI: 61.7%-86.2%) for advanced adenomas at 90% specificity in external validation.

The company targets average-risk adults aged 45 and older — a population of 125+ million Americans recommended for routine colorectal cancer screening under USPSTF, NCCN, and American Cancer Society guidelines — for whom colonoscopy compliance is below 40%. A secondary use case is post-polypectomy surveillance risk stratification. FirstSight is physician-ordered and not available direct-to-consumer; revenue is generated through laboratory diagnostic testing services on samples sent to the Sunnyvale lab. CellMax secured FDA Breakthrough Device Designation for FirstSight in August 2021 and entered a strategic development and commercialization partnership with Sebela Pharmaceuticals in March 2021 alongside its Series C financing.

The company is led by CEO and co-founder Atul Sharan, with CSO and VP of R&D Rui Mei (PhD, ex-Centrillion Biosciences), Chief Technology Advisor John Sninsky (PhD, former CSO of CareDx, 30+ years across Roche Molecular Systems, Celera, and Quest Diagnostics), and Sr. VP of Clinical Studies and Biostatistics Drew Watson (PhD, ex-Genomic Health where he led the pivotal Oncotype DX trial). The company operates with 51-100 employees, a global R&D team, and protects its core technology with 16 patents covering the microfluidic chip, colon-specific antibodies, and air-foam release mechanism.

CellMax Life firmographics

Firmographics
Name
CellMax Life
Legal name
CellMax, Inc.
Website
https://cellmaxlife.com
Company type
Private
Founded year
2012
Operating status
Operating
Headcount range
11–50 employees
Short description
CellMax Life is a private molecular diagnostics company that has developed the FirstSightCRC blood test, a non-invasive multimodal liquid biopsy using its proprietary CMx circulating epithelial cell platform for early detection of colorectal cancer and pre-cancerous adenomas, serving average-risk adults aged 45 and over through physician-ordered testing.
Ownership category
akta.pro rank

CellMax Life industry classification

Industry
Product category
Cancer Diagnostics
NAICS
Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAAANAG
Liquid Biopsy & Minimal Residual Disease (MRD) Precision Testing
SECONDARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
SECONDARYHLAAAMAH
Liquid Biopsy Biomarkers (ctDNA/ctRNA/CTCs/exosomes)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAGAEAB
Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics

Keywords

  • Liquid biopsy diagnostics
  • Colorectal cancer screening
  • Circulating tumor cells
  • Early cancer detection
  • Molecular diagnostic tests

Where CellMax Life is headquartered

Location

Headquarters

HQ city
Sunnyvale
HQ country
United States
HQ region
North America

Offices2 records

Markets served

CellMax Life business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. Laboratory Diagnostic Testing Services: CellMax Life generates revenue through providing CLIA-certified and CAP-accredited laboratory testing services for its FirstSight blood test. The test is performed on blood samples collected by healthcare providers and processed in their certified laboratory.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

CellMax Life product offering

Product offering

Core offering

CellMax Life develops and commercializes non-invasive blood-based diagnostic tests for early cancer detection, with its flagship FirstSightCRC test screening for colorectal cancer and precancerous adenomas. The tests leverage a proprietary Circulating Epithelial Cell Bio-Mimetic (CMx) platform combining microfluidic cell capture with multimodal biomarker (mutation, methylation) analysis. Testing is performed in the company's CLIA-certified and CAP-accredited laboratory in Sunnyvale, California, with samples ordered through healthcare providers.

Product overview

CellMax Life offers a portfolio of non-invasive blood tests for cancer screening and early detection, anchored by the FirstSightCRC blood test for colorectal cancer and pre-cancer detection. The company's proprietary CMx platform (Circulating Epithelial Cell Bio-Mimetic) forms the core technology foundation, utilizing a patented microfluidic chip with colon-specific antibodies and air-foam cell release mechanism. The test analyzes circulating gastrointestinal epithelial cells (CECs) along with mutation and methylation data through proprietary algorithms. The company also operates multi-biomarker platforms covering next generation sequencing (NGS), methylation, and protein expression. CellMax Life is headquartered in Sunnyvale, California with a CLIA certified and CAP accredited laboratory at this location.

Differentiator

Problem solved

Functional benefit

Brands

  • FirstSight: FirstSight™ - the first blood test for colon cancer screening and prevention. A multimodal liquid biopsy test that detects circulating gastrointestinal epithelial cells (CECs) and genomic markers (mutations and methylation) in a single blood sample for early detection of colorectal cancer and precancerous adenomas.

Products and services

  • FirstSightCRC (FirstSight™) A non-invasive multimodal blood test for early detection of colorectal cancer and pre-cancerous adenomas (precancerous polyps). The test uses the proprietary CMx platform to detect circulating precancer and cancer cells shed into the blood during early cancer development, combining circulating gastrointestinal epithelial cell (CEC) detection with mutation and methylation analysis. Reports results as positive or negative.
  • Multi-biomarker Platforms Comprehensive biomarker detection platforms covering precancer and cancer cell detection, next generation sequencing (NGS), methylation, and protein expression platforms for multi-marker cancer screening and detection.

Quantifiable outcome

  • Reduces mortality from colorectal cancer by 53% through adenoma detection and removal
  • +2 more outcomes

Companies that use CellMax Life

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles2 records

CellMax Life technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

CellMax Life partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Sebela PharmaceuticalscoreStrategic or Co-development Partner · 23 March 2021Strategic development and commercialization partnership for FirstSight blood test for detection of colorectal cancer and pre-cancer. CellMax Life closed Series C financing to accelerate development and regulatory approvals of FirstSight in conjunction with this partnership.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

CellMax Life competitors and assessment

Company assessment

Broad incumbents

  • Natera: Clinical-grade molecular diagnostics company offering cell-free DNA tests across oncology, women's health, and organ health. Comparable to CellMax in deploying proprietary cfDNA/cell-based assays from a CLIA-certified lab and selling into physician channels.
  • CareDx: Specialty diagnostics company focused on transplant and immune disorder monitoring, with prior CSO Dr. John Sninsky now advising CellMax. Comparable as a publicly traded specialty molecular diagnostics company operating CLIA-certified lab services and engaging in PMA-style clinical evidence generation.
  • Quest Diagnostics: One of the largest clinical laboratory services companies in the U.S., offering a broad menu of diagnostic tests including oncology and genetics. Comparable to CellMax as a scaled reference lab operator with physician ordering workflows and payer relationships.
  • Genomic Health (Exact Sciences subsidiary): Now part of Exact Sciences, Genomic Health pioneered Oncotype DX and established clinical-grade genomic diagnostics with Medicare coverage. Relevant incumbent comparable to CellMax in operating CLIA-certified molecular diagnostic labs and pursuing reimbursement-driven commercial models.

Emerging players

  • GRAIL: Developer of the Galleri multi-cancer early detection blood test using methylation-based ctDNA analysis. Comparable to CellMax in targeting non-invasive blood-based cancer screening, though broader in indication scope (multi-cancer vs. CRC-focused).
  • AnchorDx: China- and U.S.-based cancer screening diagnostics company developing blood-based methylation assays for early cancer detection. Comparable to CellMax in pursuing non-invasive blood-based cancer screening, particularly relevant given CellMax's Taiwan R&D footprint.
  • Freenome: Multiomics blood-based early cancer detection company with a lead colorectal cancer screening program (PREEMPT CRC). Comparable to CellMax in deploying proprietary blood-based biomarker assays for early cancer detection and competing for similar screening populations.
  • Adela: Early-detection company developing a blood-based methylated DNA platform for multi-cancer detection. Comparable to CellMax in deploying next-generation liquid biopsy technology for early cancer screening from a clinical-grade lab.

Direct peers

  • Exact Sciences: Developer of Cologuard, the leading FDA-approved non-invasive stool-based colorectal cancer screening test, and Thrive Earlier Detection (acquired). Direct competitor to FirstSight in the non-invasive CRC screening category, with established Medicare coverage and broad physician adoption.
  • Guardant Health: Developer of the Shield blood-based CRC screening test and a leading liquid biopsy oncology diagnostics franchise. Directly comparable to CellMax in blood-based CRC detection technology, target customer (prescribing physicians), and business model (lab-developed test services).

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

CellMax Life social profiles

Digital presence

CellMax Life compliance and trust

Trust signal

Compliance4 records

CellMax Life financial estimates

Financial estimate

Revenue estimate

Valuation estimate

CellMax Life leadership team

Management profile

Number of profiles

Profiles5 records

CellMax Life funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

CellMax Life M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CellMax Life

What does CellMax Life do?

CellMax Life develops and commercializes non-invasive blood-based diagnostic tests for early cancer detection, with its flagship FirstSightCRC test screening for colorectal cancer and precancerous adenomas. The tests leverage a proprietary Circulating Epithelial Cell Bio-Mimetic (CMx) platform combining microfluidic cell capture with multimodal biomarker (mutation, methylation) analysis. Testing is performed in the company's CLIA-certified and CAP-accredited laboratory in Sunnyvale, California, with samples ordered through healthcare providers.

Is CellMax Life a public or private company?

CellMax Life is a private company. It is classified as venture growth investor backed and is currently operating.

When was CellMax Life founded?

CellMax Life was founded in 2012. It employs 11 to 50 people.

Where is CellMax Life based?

CellMax Life is headquartered in Sunnyvale, United States, in the North America region.

How does CellMax Life make money?

One revenue line is on record: laboratory Diagnostic Testing Services.

Who are CellMax Life's main competitors?

Broad incumbents on record are Natera, CareDx, Quest Diagnostics and Genomic Health (Exact Sciences subsidiary). Emerging players are GRAIL, AnchorDx, Freenome and Adela. Direct peers are Exact Sciences and Guardant Health.

Does CellMax Life have an API?

No public API is recorded for CellMax Life.

What industry is CellMax Life in?

CellMax Life's product category is Cancer Diagnostics. Its primary akta.pro industry code is HLAAANAG, Liquid Biopsy & Minimal Residual Disease (MRD) Precision Testing, with a secondary code of HLAAALAE, Oncology Diagnostics (tumor profiling, MRD, liquid biopsy). Its NAICS code is 621511 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireCellMax Life and Sebela Pharmaceuticals Enter Strategic Development and Commercialization Partnership for FirstSight™ Blood Test for Detection of Colorectal Cancer and Pre-CancerCellMax Life and Sebela Pharmaceuticals have entered a strategic development and commercialization partnership for FirstSight, a blood test designed to detect colorectal cancer and pre-cancerous polyps. Concurrently, CellMax Life closed a Series C financing round that included participation from Aflac Ventures to accelerate clinical development and regulatory approval processes. Under the agreement, Sebela Pharmaceuticals will handle the commercialization of the test in the United States following FDA approval.PrwebCellMax Life Shares Additional Data from its U.S. Study for FirstSight Blood Test to Detect Colorectal Precancerous Adenomas and CancerCellMax Life released additional data from its U.S. Zenith study regarding the efficacy of its FirstSight blood test for detecting colorectal precancerous adenomas and cancer, presented at the ASCO Annual Meeting. The study demonstrated a significant association between test scores and polyp characteristics, suggesting potential superiority over current fecal immunochemical tests for high-specificity detection. This development aims to improve patient compliance with surveillance intervals following polypectomy by offering a convenient noninvasive screening option.PR NewswireCellMax Life Launches Zenith, a U.S. Clinical Study for the Advancement of Blood Tests for Early Cancer Detection, With the Goal of Seeking FDA ApprovalCellMax Life announced the launch of Zenith, a U.S. clinical study for its circulating tumor cell (CTC) blood test designed for early colorectal cancer detection, partnering with Stanford Medicine, the VA Palo Alto Health Care System, Johns Hopkins, and the University of Southern California. The test demonstrated 84 to 88 percent accuracy in detecting early-stage colorectal cancer in a prior Asian trial presented at the 2018 ASCO Gastrointestinal Cancer Symposium, and is priced at under $200 with results derived from a single blood draw. The company plans to pursue simultaneous FDA approval and Centers for Medicare and Medicaid Services coverage determination through the Parallel Review Program.PR NewswireStudy Presented at ASCO GU 2018 Shows Circulating Tumor Cell Blood Test May Enhance Utility of PSA Screening By Reducing Unnecessary Prostate Biopsies By Up To 90%CellMax Life announced results from a 200-patient study showing its circulating tumor cell (CTC) blood test can detect early-stage prostate cancer with 80% sensitivity and more than 90% specificity in patients with indeterminate PSA levels. The test demonstrated potential to reduce unnecessary prostate biopsies by up to 90%, addressing a clinical unmet need where three out of four men with gray zone PSA results currently receive negative biopsies after undergoing an invasive procedure. The company plans to expand the study to 250 additional patients and extend trials to the United States, with a goal of offering the test at a $150 price point.PrwebCellMax Life Leads Liquid Biopsy Discussion with Chief Medical Officer of ASCO and Industry Leaders at 2018 Precision Medicine World ConferenceCellMax Life CEO Atul Sharan led a panel discussion on liquid biopsies at the 2018 Precision Medicine World Conference alongside executives from ASCO, IncellDx, and Cellworks. The company showcased its proprietary CTC blood test, which claims to detect early-stage cancer with high accuracy, following positive results from a recent study presented at an ASCO gastro-intestinal conference. This event highlights CellMax Life's strategic push to promote its non-invasive diagnostic platform for early cancer detection and therapy selection.The NationalBlood test shows promise in early detection of cancerJohns Hopkins University scientists reported that their experimental blood test detected approximately 70% of eight common cancer types in a study of over 1,000 patients. The test identifies mutations in 16 genes and measures eight proteins, with validation studies now underway involving 10,000 patients to assess its effectiveness in the general population. Concurrently, Taiwan-based CellMax Life presented results for its own liquid biopsy test, which showed high accuracy for detecting colon cancer precursors.VC News DailyCellMax Life Secures $9M Series A-1 RoundCellMax Life, a precision cancer blood-testing company headquartered in Sunnyvale, California, announced $9 million in Series A-1 venture funding, bringing its total venture investment to $14 million. The round was led by Silicon Valley venture capital firm Artiman and several Taiwanese investors, including Stan Shih, founder of Acer, Inc. The company plans to use the funding for product development, ongoing clinical trials, and commercialization of its blood test portfolio, including CellMax CRC-Protect for early colorectal cancer detection.